20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T35554 | GSK-3β inhibitor 3 | Apoptosis , GSK-3 | |
GSK-3β inhibitor 3 is a covalent inhibitor (IC50: 6.6 μM) of glycogen synthase kinase 3β (GSK-3β) that is potent, selective, and irreversible.GSK-3β inhibitor 3 can be used to study acute promyelocytic leukemia. | |||
T11467 | GSK-3β inhibitor 1 | GSK-3 | |
GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy. | |||
T9178 | (E/Z)-GSK-3β inhibitor 1 | GSK-3β inhibitor 1 | GSK-3 |
(E/Z)-GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy. | |||
T9725 | GSK-3β inhibitor 10 | Others | |
GSK-3β inhibitor 10 has skin-whitening, anti-oxidizing and PPAR activities. | |||
T6187 | TDZD-8 | GSK-3β Inhibitor I,NP 01139 | GSK-3 |
TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. | |||
T1881 | AR-A014418 | AR 0133418,GSK-3beta Inhibitor VIII,AR 014418,GSK 3β inhibitor VIII | GSK-3 |
AR-A014418 (GSK 3β inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor. | |||
T14066 | 9-ING-41 | Apoptosis , GSK-3 , Autophagy | |
9-ING-41 is a glycogen synthase kinase-3 inhibitor. | |||
T64366 | GSK3-IN-4 | GSK-3 | |
GSK3-IN-4 is a GSK-3 inhibitor with IC50 of 0.101-1 μM of GSK-3α and GSK-3β in Calipe Assay. | |||
T22657 | Laduviglusib trihydrochloride | CT99021 trihydrochloride,CHIR 99021 trihydrochloride,CHIR 99021 trihydrochloride (252917-06-9 free base) | GSK-3 , Wnt/beta-catenin |
Laduviglusib trihydrochloride (CT99021 trihydrochloride) is a selective glycogen synthase kinase 3 (GSK-3) inhibitor with IC50s of 10 nM and 6.7 nM for GSK-3α and GSK-3β. Laduviglusib trihydrochloride inhibits human GSK-... | |||
T9611 | PF-04802367 | GSK-3 | |
PF-04802367 is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. It shows desirable central nervous system (CNS) properties and ... | |||
T77341 | GSK-3 inhibitor 4 | GSK-3 , CDK | |
GSK-3 inhibitor 4 is an orally active and brain-permeable triple inhibitor of GSK-3, CDK2 and CDK5 with inhibitory effects on GSK-3β, GSK-3α, CDK2 and CDK5, with IC50 values of 0.56 nM, 0.45 nM, 0.47 μM, 0.68 μM, respect... | |||
T10202 | A 1070722 | GSK-3 | |
A 1070722 is a potent and selective GSK-3 inhibitor, with a Ki of 0.6 nM for both GSK-3α and GSK-3β. It can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for... | |||
T14613 | BIP-135 | GSK-3 | |
BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor. With IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect[1]. | |||
T77342 | GSK-3 inhibitor 3 | GSK-3 , Microtubule Associated | |
GSK-3 inhibitor 3 is a selective, orally active, brain-permeable GSK-3 inhibitor that inhibits GSK-3α and GSK-3β with IC50s of 0.35 nM and 0.25 nM, respectively.GSK-3 inhibitor 3 reduces the phosphorylation level of tau ... | |||
T6358 | 1-Azakenpaullone | azakenpaullone | GSK-3 |
1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25. | |||
T1957 | AZD2858 | GSK-3 | |
AZD2858 is a selective GSK-3 inhibitor, inhibiting tau phosphorylation at the S396 site and activating Wnt signaling pathway. | |||
T2608 | CHIR-98014 | CHIR 98014,CT98014,CHIR98014 | FGFR , GSK-3 , Src , S6 Kinase |
CHIR-98014 (CT98014) is a selective GSK3 inhibitor; potentiate insulin activation of glucose transport and utilization in vitro and in vivo. | |||
T1755 | LY2090314 | GSK-3 | |
LY2090314, an effective GSK-3α/β inhibitor (IC50: 1.5 nM/0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, a... | |||
T2378 | RGB-286638 free base | GSK-3 , MEK , JAK , CDK | |
RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 a... | |||
T21377 | Aloisine A | ||
Aloisine A is a potent and selective CDK/GSK-3 inhibitor. IC50 data of Aloisine A: Cdk1/cyclin B (IC50: 150nM), Cdk2/cyclin A (IC50: 120nM), Cdk2/cyclin E (IC50: 400nM), Cdk5/p25 (IC50: 200nM), Cdk5/p35 (IC50: 160nM), GS... |